['nonproliferative diabetic retinopathy']
['intravitreal aflibercept injection [iai]', 'sham']

        Key Inclusion Criteria:

          1. Men or women ≥18 years of age with type 1 or 2 diabetes mellitus who have moderately
             severe to severe nonproliferative diabetic retinopathy (NPDR) [(diabetic retinopathy
             severity scale (DRSS) levels 47 or 53)], confirmed by the central reading center, in
             whom panretinal photocoagulation (PRP) can be safely deferred for at least 6 months
             per the investigator

          2. Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS)
             letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40
             or better)

        Key Exclusion Criteria:

          1. Presence of diabetic macular edema (DME) threatening the center of the macula in the
             study eye

          2. Evidence of retinal neovascularization on clinical examination or Fluorescein
             Angiography (FA)

          3. Any prior focal or grid laser photocoagulation or any prior PRP in the study eye

          4. Any prior systemic anti-vascular endothelial growth factor (VEGF) treatment or
             intravitreal (IVT) anti-VEGF treatment in the study eye

          5. Any prior intraocular steroid injection in the study eye

          6. Current anterior segment neovascularization (ASNV), vitreous hemorrhage, or tractional
             retinal detachment visible at the screening assessments in the study eye

        Note: Other inclusion/ exclusion criteria apply
      